Expression and Localization of Ferritin-Heavy Chain Predicts Recurrence for Breast Cancer Patients with a Mutation.

The ferritin-heavy chain (FTH1) is the catalytic subunit of the ferroxidase ferritin, which prevents oxidative DNA damage via intracellular iron storage. FTH1 was shown to be a prognostic marker for triple-negative breast cancer (BC) patients and associated with an enrichment of CD8+ effector T cells. However, whether the expression and localization of FTH1 are also associated with clinical outcome in other BC subtypes is unknown. Here, we investigated the association of FTH1 with time to survival in BCs from 222 mutation carriers by immunohistochemistry on tissue microarrays. In addition, for 51 of these patients, the association between FTH1 and specific subsets of T cells was evaluated on whole slides using automatic scoring algorithms. We revealed that nuclear FTH1 (nFTH1) expression, in multivariable analyses, was associated with a shorter disease-free (HR = 2.71, 95% CI = 1.49-4.92, = 0.001) and metastasis-free survival (HR = 3.54, 95% CI = 1.45-8.66, = 0.006) in patients carrying a mutation. However, we found no relation between cytoplasmic FTH1 expression and survival of mutation carriers. Moreover, we did not detect an association between FTH1 expression and the amount of CD45+ ( = 0.13), CD8+ ( = 0.18), CD4+ ( = 0.20) or FOXP3+ cells ( = 0.17). Consequently, the mechanism underlying the worse recurrence-free survival of nFTH1 expression in mutation carriers needs further investigation.